Thermo Fisher Scientific Inc. (NYSE:TMO) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 5,405,049 shares, a growth of 47.8% from the November 30th total of 3,657,291 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily volume of 2,174,965 shares, the short-interest ratio is presently 2.5 days.

Several research analysts recently commented on TMO shares. Leerink Swann increased their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research report on Monday, October 9th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective on the stock in a research note on Thursday, September 21st. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. Barclays restated an “overweight” rating and issued a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Finally, Evercore ISI initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $212.21.

Thermo Fisher Scientific (NYSE:TMO) opened at $202.72 on Tuesday. The firm has a market capitalization of $80,860.00, a P/E ratio of 34.42, a PEG ratio of 1.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific has a 52 week low of $140.00 and a 52 week high of $203.24.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.03 earnings per share. research analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.

In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Research Global Investors increased its stake in Thermo Fisher Scientific by 29.8% during the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares during the period. Janus Henderson Group PLC increased its stake in Thermo Fisher Scientific by 2,058.1% during the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares during the period. Veritas Asset Management LLP increased its stake in Thermo Fisher Scientific by 112.4% during the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares during the period. Meritage Group LP bought a new position in Thermo Fisher Scientific during the 3rd quarter worth $201,383,000. Finally, Capital World Investors increased its stake in Thermo Fisher Scientific by 6.1% during the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after acquiring an additional 671,637 shares during the period. Institutional investors own 86.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc. (TMO) Short Interest Update” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with's FREE daily email newsletter.